By Kestutis Balciunas·Reviewed August 24, 2026

Healthcare ETFs: Medical and Biotech Funds for European Investors

European investors searching for a pharma ETF will not find a pure one. No meaningful pharmaceutical-only UCITS ETF exists; what is available is broad healthcare funds whose largest holdings happen to be pharmaceutical companies, alongside a thinner shelf of biotech and thematic options. The practical shortlist is short: the Xtrackers MSCI World Health Care fund for global exposure, the iShares STOXX Europe 600 Health Care line for European-only, and a handful of thematic funds beside them.

This guide works through what each of those actually holds, how the sector behaves (defensive on the pharma side, emphatically not on the biotech side), why the famous US biotech funds IBB and XBI are closed to European retail buyers, and how much of a portfolio a sector bet like this deserves. The original overview follows.

Healthcare exchange-traded funds (ETFs) give European investors exposure to the medical and biotechnology sectors. The global pharmaceutical market reached $1.38 trillion in 2024. Moreover, European healthcare investment exceeded €8 billion in EU-funded projects alone. These funds give diversified access to companies leading medical innovation. European investors can choose between regional UCITS-compliant funds and global healthcare ETFs. This range covers everything from established pharmaceutical giants to cutting-edge biotech startups. Many of these smaller firms are developing breakthrough treatments.

Healthcare ETF investment infographic with medical symbols and European flags

Understanding Healthcare ETFs

Healthcare ETFs are investment funds. They track baskets of stocks from companies in medical research, pharmaceutical development, medical device manufacturing, and healthcare services. These funds operate under the “razor-and-blade” business model typical of the healthcare sector. In practice, equipment sales often generate recurring revenue from consumables and services. For European investors, the appeal centers on a sector that benefits from demographic trends and technological innovation. Notably, the sector also delivers consistent demand regardless of economic cycles.

The Global Industry Classification Standard (GICS) divides the healthcare sector into several sub-segments. These include pharmaceuticals, biotechnology, medical devices, healthcare equipment and supplies, healthcare providers and services, and life sciences tools. This classification helps investors understand exactly what they own when selecting healthcare ETFs.

New on the site: my VanEck thematic ETF guide.

European Healthcare ETF Landscape

Major European Healthcare ETFs

European investors can access several UCITS-compliant healthcare ETFs. These funds provide exposure to both regional and global healthcare markets. The Xtrackers MSCI World Health Care UCITS ETF stands as the largest option. It holds €2.28 billion in assets under management and charges a competitive 0.25% expense ratio. This fund delivers global healthcare exposure. Crucially, it also maintains the regulatory compliance that European investors require. Additionally, investors gain from the freedom24 advantages for ETF investors, which include reduced trading fees and access to a wider array of investment options. These benefits enhance the overall experience. As a result, capital flows more efficiently within the healthcare sector. Furthermore, UCITS compliance ensures the security and transparency essential for long-term growth.

The iShares STOXX Europe 600 Health Care UCITS ETF offers more focused European exposure. It holds €721 million in assets and tracks 55 European healthcare companies. Although it carries a higher expense ratio of 0.46%, this fund provides direct access to European healthcare leaders. These leaders include Novo Nordisk, Roche, AstraZeneca, and Novartis.

For investors seeking European healthcare exposure with ESG screening, the Xtrackers MSCI Europe Health Care Screened UCITS ETF offers a strong choice. It provides access to 29 holdings. Crucially, it excludes companies involved in weapons, tobacco, and thermal coal. This fund maintains a low 0.17% expense ratio. Since its 2007 launch, it has attracted €288 million in assets.

The SPDR MSCI Europe Health Care UCITS ETF rounds out the major European options. It carries a 0.18% expense ratio and holds €409 million in assets. This fund tracks the MSCI Europe Health Care 35/20 Capped Index. The index limits the largest holding to 35% and other holdings to 20%. Consequently, it provides better diversification than market-cap weighted alternatives.

Geographic Distribution and Holdings

European healthcare ETFs typically show strong concentration in Switzerland. The country accounts for roughly 37-38% of holdings across major funds. This reflects the dominance of Swiss pharmaceutical giants like Roche and Novartis. The United Kingdom holds the second-largest allocation at around 21-23%. Denmark follows at approximately 15% due to Novo Nordisk’s significant weight.

Sector composition favors pharmaceuticals heavily. They typically make up 75-76% of European healthcare ETFs. Healthcare equipment and supplies account for roughly 14%. By contrast, biotechnology represents a smaller 3-4% allocation. This distribution reflects the maturity of European pharmaceutical companies. In short, it differs from the more biotech-heavy composition of US healthcare indices.

Biotech ETFs: High-Risk, High-Reward Opportunities

Modern biotech laboratory showing DNA research and molecular technology

Leading Biotech ETF Options

Biotech ETFs give European investors exposure to companies developing innovative treatments through biological processes. However, they carry significantly higher volatility than broader healthcare funds. The iShares Biotechnology ETF (IBB) remains the largest biotech ETF globally with $7.1 billion in assets. Although it declined 7.5% in 2023, it has shown signs of recovery.

For the volatility and max-drawdown numbers head-to-head, use the volatility & drawdown analyzer.

The SPDR S&P Biotech ETF (XBI) provides pure biotech exposure through equal weighting. This approach gives smaller companies more influence than traditional market-cap weighting. With $7.0 billion in assets and a 0.35% expense ratio, XBI gained 9.06% year-to-date through October 2024.

More specialized biotech ETFs include the Virtus LifeSci Biotech Clinical Trials ETF (BBC). It focuses on companies with drugs in preclinical testing or research stages. This high-risk fund gained 19.62% year-to-date through October 2024. However, it carries significant concentration risk with only $11.7 million in assets.

The ALPS Medical Breakthroughs ETF (SBIO) targets companies with drugs in Phase II or III clinical trials. It represents a middle ground between early-stage and established biotech companies. With 16.81% returns through October 2024 and $117.6 million in assets, SBIO offers exposure to companies closer to potential drug approvals.

Biotech Investment Considerations

Biotech ETFs carry unique risks that European investors must grasp. Clinical trial failures can devastate individual companies and drag down ETF performance. Moreover, regulatory delays from agencies like the FDA or EMA can hit entire portfolios. The Nasdaq Biotechnology Index shows both the potential and volatility of biotech investing. It gained nearly 44% over three years while experiencing significant short-term swings.

The diversification benefits of biotech ETFs help mitigate the extreme volatility of individual biotech stocks. Rather than betting on a single company’s drug development success, investors gain exposure to dozens of companies at various stages. This approach reduces the impact of any single failure. Importantly, it also maintains upside potential from breakthrough treatments.

European biotech investment has shown particular strength in 2024. Venture capital funding exceeded €5 billion in the first half of the year. Major hubs in the United Kingdom, Germany, France, and Switzerland continue attracting significant investment. For example, companies like BioNTech secured €1 billion funding rounds to expand mRNA therapy pipelines.

Performance Analysis and Market Trends

Recent Performance Patterns

Healthcare ETF performance has shown mixed results in recent years. Sector-specific headwinds have affected different sub-segments. The MSCI World Health Care index declined 14.11% over one year through June 2025. However, it kept positive 24.73% returns over five years. This performance reflects challenges from biosimilar competition affecting established biologics. Additionally, pricing pressure from healthcare payers contributed.

European healthcare stocks faced particular pressure in 2024. The STOXX Europe 600 Health Care index experienced volatility amid concerns about drug pricing reforms and patent expirations. However, Morgan Stanley upgraded European medtech stocks to “attractive” in early 2025. The bank projected 6% organic growth and margins exceeding 18% for the average medtech company.

Biotech ETFs have shown more dramatic performance swings. For example, the best-performing Virtus LifeSci Biotech Clinical Trials ETF gained over 19% through October 2024. By contrast, other biotech funds remained negative. This divergence reflects the high-risk, high-reward nature of biotech investing. Crucially, it also highlights the importance of timing and fund selection.

Dividend Considerations

Healthcare ETFs typically provide modest dividend yields. Most European healthcare funds yield 1-2% annually. The iShares STOXX Europe 600 Health Care UCITS ETF distributes dividends at least annually. By contrast, accumulating versions reinvest dividends automatically. This dividend income, while not substantial, provides some downside protection during market volatility.

Pharmaceutical companies generally offer more consistent dividend payments than biotech companies. Biotech firms typically reinvest earnings in research and development. European pharmaceutical giants contribute meaningful dividend income to healthcare ETFs. For example, Sanofi yields 4.72%, GSK yields 4.6%, and Roche yields 3.77%.

Growth Prospects and Market Drivers

Several long-term trends support healthcare ETF performance for European investors. The aging European population creates consistent demand for medical treatments and devices. Moreover, breakthrough technologies in gene therapy, immunotherapy, and digital health drive innovation. Healthcare spending typically rises regardless of economic conditions. Consequently, the sector offers defensive characteristics during market downturns.

The European medical device market represents 26.1% of the global market. It trails only the United States at 47.2%. This substantial market presence combines with strong regulatory frameworks and research infrastructure. As a result, European healthcare companies are positioned for continued growth.

Artificial intelligence integration in drug discovery represents a major growth catalyst. European biotech companies increasingly leverage AI to accelerate research timelines and improve success rates. Climate-focused biotechnology also emerges as a European strength. For example, companies are developing solutions for sustainable agriculture and environmental remediation.

Investment Strategies and Risk Management

Portfolio Allocation Approaches

European investors should consider healthcare ETF allocation as part of a diversified portfolio. Financial advisors typically recommend healthcare exposure of 5-15% for growth-oriented portfolios. Higher allocations suit investors comfortable with sector concentration. By contrast, conservative investors might prefer broad healthcare ETFs over specialized biotech funds to reduce volatility.

Core-satellite approaches work well for healthcare investing. Investors can use broad healthcare ETFs as core holdings. Then they add specialized biotech or medical device ETFs as satellite positions. This strategy delivers stable healthcare exposure. Additionally, it allows tactical allocation to higher-growth segments based on market conditions and risk tolerance.

Geographic diversification within healthcare allocations can reduce concentration risk. For example, European investors might combine European-focused healthcare ETFs with global healthcare funds. This approach balances regional exposure. Moreover, it maintains cost efficiency through ETF structures.

Risk Factors and Mitigation

Healthcare ETFs face several specific risks that investors must understand. Regulatory risk represents the most significant concern. Drug approvals, pricing decisions, and safety issues can dramatically impact company valuations. The European Medicines Agency (EMA) and national healthcare systems wield considerable influence. Their approval and reimbursement decisions can shape company prospects.

Patent cliff risk affects pharmaceutical companies. Blockbuster drugs lose exclusivity to generic competition over time. European pharmaceutical companies face ongoing pressure from biosimilar competition. This particularly affects established biologics from firms like Roche and Novartis. However, longer exclusivity periods for biologics offer some protection compared to traditional pharmaceuticals.

Currency risk affects European investors in global healthcare ETFs. Many healthcare companies generate significant revenue in US dollars. Currency-hedged versions of healthcare ETFs can reduce this risk. However, they typically carry higher expense ratios. Moreover, they may reduce returns during favorable currency movements.

Concentration risk varies significantly between healthcare ETF approaches. Market-cap weighted funds may show heavy concentration in the largest pharmaceutical companies. By contrast, equal-weighted approaches like XBI provide broader exposure. However, they may increase volatility through smaller company exposure.

Tax Considerations for European Investors

UCITS Compliance and Tax Efficiency

European healthcare ETFs structured as UCITS funds provide significant tax advantages for EU investors. They benefit from favorable withholding tax treatment and regulatory compliance. Irish-domiciled UCITS ETFs typically receive reduced US withholding tax rates. By contrast, direct investment in US healthcare stocks faces higher rates.

Accumulating vs. distributing fund structures offer different tax implications. Accumulating healthcare ETFs reinvest dividends automatically. This may provide tax deferral benefits in jurisdictions where capital gains receive preferential treatment over dividend income. By contrast, distributing versions provide regular income but may trigger annual tax obligations.

Tax reporting compliance varies by jurisdiction. Major healthcare ETF providers typically meet reporting requirements for Germany, Austria, Switzerland, and other European markets. This compliance reduces administrative burden for investors. Moreover, it ensures proper tax treatment.

Domicile Considerations

Fund domicile significantly impacts tax efficiency for European investors. Irish-domiciled healthcare ETFs typically offer the best combination of regulatory compliance and tax efficiency for EU investors. Luxembourg-domiciled funds provide similar benefits. They also meet specific regulatory requirements in certain jurisdictions. Additionally, Irish and Luxembourg-domiciled funds reduce withholding taxes on dividends. As a result, overall returns improve for investors. This proves particularly relevant for bond ETFs for European investors, which often face significant tax implications that can erode potential gains. Consequently, selecting the right fund domicile is crucial for optimizing investment strategies within the European market. Moreover, investors should consider strategies like spousal contributions for tax benefits. Such techniques can further optimize tax efficiency within these domiciles. By leveraging these approaches, investors can maximize contributions and take advantage of available allowances. Ultimately, this enhances portfolio growth potential. Understanding the nuances of fund domicile and tax strategies is essential for informed investment decisions in Europe.

German-domiciled healthcare ETFs like the iShares STOXX Europe 600 Health Care UCITS ETF (DE) may offer advantages for German investors. They provide simplified tax reporting and local regulatory compliance. However, these funds typically carry higher expense ratios than their Irish counterparts.

Future Outlook and Emerging Trends

Technological Innovation Impact

Healthcare ETFs benefit from accelerating technological innovation across multiple areas. Gene therapy advances from companies like BioNTech continue attracting substantial investment. For example, the company secured €1 billion in funding to expand its mRNA therapy pipeline beyond COVID-19 vaccines. European gene therapy companies increasingly compete with US counterparts. Their focus includes treatments for cancer and rare diseases.

Digital health integration accelerates across European healthcare systems. EU initiatives support this shift. For example, the European Health Data Space (EHDS) targets 100% electronic health record access by 2030. This digitalization trend benefits healthcare technology companies. Moreover, it supports efficiency improvements across the sector.

Personalized medicine represents a major growth area where European companies excel. Their strength shows particularly in diagnostics and companion therapeutics. For example, Roche leverages its combined pharmaceutical and diagnostics expertise. This positions the firm to develop personalized treatment approaches that command premium pricing.

Regulatory Environment Evolution

European healthcare regulation continues evolving. It seeks to balance innovation incentives with cost control pressures. The European Medicines Agency increasingly adopts adaptive approval pathways. These pathways can accelerate breakthrough therapy access while maintaining safety standards. Consequently, these regulatory improvements support biotech company success rates. Moreover, they reduce development timelines.

Pricing and reimbursement policies across European healthcare systems create both challenges and opportunities. Cost containment pressures affect traditional pharmaceuticals. However, innovative treatments in gene therapy and immunotherapy often receive favorable reimbursement terms. These terms reflect their clinical value.

Market Consolidation Trends

Merger and acquisition activity in European healthcare continues. Larger companies seek innovative assets, and smaller companies need capital for development. This consolidation typically benefits diversified healthcare ETFs. Specifically, it provides exit opportunities for biotech holdings. Moreover, it strengthens pharmaceutical company pipelines.

Public-private partnerships increasingly support European biotech development. For example, the EU’s Horizon Europe Program offers a €95.5 billion research and innovation budget. These partnerships reduce individual company risk. Additionally, they accelerate innovation timelines.

Conclusion and Investment Recommendations

Healthcare ETFs offer European investors compelling access to one of the most innovative and resilient sectors. Demographic trends, technological advancement, and regulatory support create favorable long-term prospects. This holds true despite near-term volatility and sector-specific challenges. Moreover, demand for quality healthcare continues to rise. Aging populations and increasing health awareness drive this growth. Consequently, investors can benefit from diversified exposure to both established companies and emerging innovators. A comprehensive sector and industry ETFs overview can help investors navigate the market landscape and identify promising opportunities. By strategically allocating resources within healthcare ETFs, investors position themselves for potential growth. At the same time, they balance risks associated with market fluctuations. Additionally, healthcare ETFs can serve as a cornerstone for European investor wealth strategies. They leverage the sector’s potential for consistent returns. By adding these funds to a well-rounded portfolio, investors can enhance overall financial resilience. Moreover, they capitalize on the long-term growth trajectory of the healthcare industry. This strategic approach mitigates risks. Crucially, it also aligns with broader economic trends that favor health innovation and accessibility.

Conservative investors should consider broad European healthcare ETFs. Examples include the Xtrackers MSCI World Health Care UCITS ETF or SPDR MSCI Europe Health Care UCITS ETF. These provide diversified exposure to established companies with reasonable expense ratios and regulatory compliance. Moreover, these funds offer stability through pharmaceutical dividend income. They also maintain growth potential through medical technology and biotech exposure.

Growth-oriented investors may benefit from combining broad healthcare exposure with specialized biotech ETFs. For example, the SPDR S&P Biotech ETF or ALPS Medical Breakthroughs ETF work well as satellite positions. This approach captures the higher growth potential of innovative therapies. At the same time, it maintains diversification across development stages and therapeutic areas.

For context: medical insurance for early retirees.

Strategic allocation of 5-15% to healthcare ETFs within diversified portfolios provides exposure to secular growth trends. Importantly, it also maintains portfolio balance. European investors should prioritize UCITS-compliant funds for tax efficiency. Moreover, they should consider currency hedging based on risk tolerance and base currency exposure. Additionally, healthcare ETFs can enhance overall volatility management during economic downturns. This sector often exhibits resilience. Investors should explore various ETF asset allocation strategies for Europe, which can be tailored to specific objectives and risk profiles. Regular portfolio reviews remain essential. They ensure alignment with changing market conditions and investment goals. Moreover, implementing strategies such as ‘etf dollarcost averaging explained‘ can further optimize timing and reduce volatility. This method allows investors to build positions gradually. Consequently, it mitigates the impact of market fluctuations. As healthcare evolves with innovations and demographic shifts, a systematic investment approach may boost long-term returns while managing risk. Additionally, investors should consider adding ETF trading strategies for liquidity to facilitate timely entry and exit points. This could involve using limit orders or market orders based on market conditions and individual liquidity needs. By focusing on both growth opportunities and liquidity management, investors can navigate the dynamic healthcare landscape more effectively. Staying informed about market dynamics is crucial. For example, accessing resources such as ‘etf flow reports for investors‘ provides valuable insights into investor sentiment and asset movement within the healthcare sector. By monitoring these reports, investors can adjust strategies in response to emerging trends. Consequently, this proactive approach aids in optimizing portfolio performance. Moreover, it helps identify potential risks that may arise from shifts in market conditions. Investors should regularly educate themselves about different approaches to healthcare investing. They should also consider an ETF investment strategy overview to identify the most suitable options for their goals. Networking with financial professionals and attending industry seminars can provide valuable perspectives on emerging trends and strategies. By staying adaptable and informed, investors can capitalize on the rapidly changing landscape of the healthcare sector.

The healthcare sector’s defensive characteristics combine well with innovation-driven growth potential. Together, they position healthcare ETFs as essential components of modern European portfolios. Volatility will continue, particularly in biotech segments. However, the long-term outlook remains favorable for investors willing to embrace the sector’s unique risk-reward profile.

Frequently asked questions

Is there an ETF for pharmaceutical companies?

Not a pure one, in UCITS form. European investors have no meaningful pharma-only UCITS ETF to buy; the closest available exposure is a broad healthcare fund whose largest weights are pharmaceutical companies. The Xtrackers MSCI World Health Care and iShares STOXX Europe 600 Health Care lines are the practical answer to a search for a pharma ETF, and their published holdings show how much of the fund is actually pharma rather than devices, insurers or biotech.

What is the best healthcare ETF for a European investor?

For global coverage, the Xtrackers MSCI World Health Care UCITS ETF is the largest and most liquid option. For European-only exposure, the iShares STOXX Europe 600 Health Care fund is the established choice, with a German-domiciled line that suits German investors’ reporting. Neither is ‘best’ in the abstract — the global fund gives you the US majors, the European fund gives you a concentrated bet on a handful of continental pharma names.

Is there a European biotech ETF?

Dedicated European biotech UCITS ETFs are thin on the ground, which is why the search so often ends at a broad healthcare fund with a biotech sleeve. The pure biotech funds with real scale — IBB and XBI — are US-listed, and that matters for availability rather than quality.

Can European investors buy IBB or XBI?

Generally no. Both are US-domiciled ETFs without a PRIIPs Key Information Document, so EU and UK retail brokers block them under the same rule that blocks VOO and SPY. The route to comparable exposure is a UCITS healthcare or thematic fund, not a workaround.

Does the Xtrackers MSCI World Health Care ETF hold Novo Nordisk?

Yes — Novo Nordisk is a constituent of the MSCI World Health Care index and so sits in the fund. Its weight moves with the share price and has swung considerably in recent years, so check the fund’s current holdings page rather than trusting any figure quoted in an article, including this one.

What is a medical ETF?

It is a loose term rather than a fund category. In practice people searching for a medical ETF want one of three things: broad healthcare (pharma, devices, insurers, services), medical devices and equipment specifically, or biotech. The three behave very differently — healthcare is a defensive sector, biotech is not — so it is worth deciding which one you actually mean before shortlisting.

Sources and further reading

• justETF — Xtrackers MSCI World Health Care UCITS ETF 1C (IE00BM67HN09) — holdings, fee and size for the largest global option
• justETF — iShares STOXX Europe 600 Health Care UCITS ETF (DE000A0Q4R36) — the established European-only line
• justETF — iShares Healthcare Innovation UCITS ETF (IE00BYZK4776) — the thematic alternative to a plain sector fund
• ESMA — European Securities and Markets Authority — the UCITS and PRIIPs framework that decides which of these funds you can buy

This guide is part of our hub on sector and thematic UCITS ETFs — browse the full cluster for related situations.

Pharma ETF vs broad healthcare ETF: which one do you want?

A pharma ETF holds drug makers — large, dividend-paying, defensive businesses like Novartis, Roche and Novo Nordisk. A broad healthcare ETF adds insurers, device makers and biotech, trading some of that stability for growth. If you searched for a pharma ETF specifically, the closest UCITS options are pharma-heavy healthcare funds (the iShares Healthcare Innovation and Xtrackers MSCI World Health Care lines above), since pure pharma-only UCITS ETFs are rare. The comparison tables show each fund’s pharma weighting.

Kestutis Balciunas
European UCITS/ETF investor with 11+ years building a global dividend and index portfolio, and founder of Financial Expert Class. I write every guide here from first-hand experience investing across EU brokers and tax regimes — not theory. More about me →